Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 1998, and the nine-month period ended on that date for Celsion Corporation (formerly Imunon, Inc., as noted in metadata, though the filing identifies the registrant as Celsion Corporation). The company focuses on developing minimally invasive thermotherapy devices for cancer and benign prostatic hyperplasia (BPH). It has ceased active sales of current equipment to concentrate resources on developing new technologies: adaptive phase array (APA) technology licensed from MIT and balloon catheter technology from MMTC, Inc.
Key Financial Metrics
| Metric | Nine Months Ended June 30, 1998 | Nine Months Ended June 30, 1997 |
|---|---|---|
| Total Revenue | $110,260 | $116,968 |
| Gross Profit | $64,760 | $70,828 |
| Net Loss | ($3,521,826) | ($1,910,892) |
| Loss Per Share (Weighted Avg) | ($0.10) | ($0.07) |
| Cash and Cash Equivalents (End of Period) | $26,241 | $120,549 |
| Net Cash Used in Operating Activities | ($2,876,226) | ($1,350,496) |
| Total Current Liabilities | $2,488,217 | $3,283,855 |
| Working Capital | ($2,147,539) | ($2,645,908) |
| Accumulated Deficit | ($18,785,349) | ($15,263,522) |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased slightly to $110,260 from $116,968. The company recorded zero revenue from equipment sales in the quarter ended June 30, 1998, as it has ceased active sales to focus on R&D.
- Increased Operating Expenses: Total operating expenses rose to $3,537,460 from $1,854,399.
- R&D: Increased significantly to $1,298,168 from $144,945 due to technology enhancements.
- SG&A: Increased to $2,239,292 from $1,709,454, driven largely by stock-based compensation for executive Spencer J. Volk ($465,500 in the quarter).
- Liquidity Deterioration: Cash balances dropped from $267,353 at the start of the period to $26,241 at June 30, 1998. The company reported a negative working capital of $2,147,539.
- Debt Reduction: Interest expense decreased to $55,367 from $120,633 due to the repayment of certain notes and conversion of debt to equity.
Outlook, Risks, and Management Commentary
- Capital Shortfall: Management explicitly states the company does not have the capital to complete necessary clinical trials or fund committed research obligations of approximately $2.37 million ($720,000 committed + $1.65 million planned) for the remainder of 1998.
- Going Concern: The company expects existing resources will not be adequate to fund operations for the next twelve months. It is dependent on raising additional capital through equity or debt financing, with no firm commitments currently in place.
- Operational Risks: Failure to secure funding could result in a breach of license agreements with MIT and MMTC, loss of research data, and inability to commercialize products.
- Legal Proceedings: The company is a defendant in a lawsuit by Eastwell Management Services, Ltd., seeking damages of $125,000 plus interest and potential consequential/punitive damages. The company denies liability.
- Management Changes: The CFO position is vacant following the resignation of Warren C. Stearns in May 1998. Two board members also resigned in July 1998.
Investor Verification Checklist
- Capital Raising Status: Verify if the company has secured the necessary funding to meet its $2.37 million research and clinical trial obligations for the remainder of 1998.
- License Compliance: Confirm the status of license agreements with MIT and MMTC, Inc., given the risk of breach due to lack of funding.
- Legal Exposure: Monitor the outcome of the Eastwell Management Services lawsuit and potential liability exposure.
- Executive Compensation: Review the impact of continued stock-based compensation on share dilution and cash flow.
- Product Timeline: Assess the realistic timeline for FDA approval and commercialization of the APA and balloon catheter technologies, noting the company's admission that it cannot predict when new equipment will be available.